Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study
Hans Christian Ring, Jonathan Thorsen, Brian Kirby, John R Ingram, Nana Aviaaja Lippert Rosenø, Nikolaj Holgersen, Valdemar Wendelboe Nielsen, David Nikolai Thein Aagaard, Julia‐Tatjana Maul, Jashin J. Wu, Jacob P. Thyssen, Alexander Egeberg, Simon Francis Thomsen
Abstract
This nationwide cohort study included 452 patients (873 treatment series) and reported drug survival data on patients with hidradenitis suppurativa treated with biologics such as adalimumab, infliximab, ustekinumab and secukinumab. The median drug survival time for adalimumab was approximately 8 months, but bio-naïve patients had a significantly longer drug survival time compared with non-naïve patients.
Topics & Concepts
MedicineUstekinumabAdalimumabSecukinumabHidradenitis suppurativaInfliximabDermatologyCohortDanishInternal medicineCohort studyPsoriasisPsoriatic arthritisDiseaseLinguisticsPhilosophyHidradenitis Suppurativa and TreatmentsMicroscopic ColitisColorectal and Anal Carcinomas